Conexeu Sciences begins early-stage development of two wound-care scaffold formats
CNXU•Conexeu Sciences began early-stage development of two collagen scaffold formats for its investigational CXU wound-care platform. Neither has undergone preclinical evaluation, and both will follow separate development and regulatory pathways from the lead candidate, whose planned FDA 510(k) submission remains targeted for the first quarter of 2027, pending required work.
1. Scaffold development begins
Conexeu Sciences began early-stage development of W.A.F.E.R. Sheet and Lattice, two fabricated collagen scaffolds extending its investigational CXU wound-care platform. Sheet targets broad wound surfaces, while Lattice is designed for large volumetric defects.
2. Separate regulatory pathways
Neither format has undergone preclinical evaluation. Initial work focuses on reproducible fabrication and characterization of structural and handling properties. The lead flowable CXU candidate remains on track for a planned FDA 510(k) submission in the first quarter of 2027, pending required work; the W.A.F.E.R. formats are excluded from that submission.



